ESMO 2017: Abemaciclib initial therapy improves outcome in endocrine-sensitive advanced breast cancer

The results of the MONARCH 3 trial, presented at the ESMO 2017 Congress in Madrid, showed that adding the cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib to endocrine therapy improved progression-free survival compared to endocrine therapy alone...

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vNWyNu
via IFTTT